Anomalously phosphorylated tau and Aβ fragments in the CSF correlates with cognitive impairment in MCI subjects
Author
dc.contributor.author
Maccioni Baraona, Ricardo
Author
dc.contributor.author
Lavados Montes, Manuel
Author
dc.contributor.author
Guillón, Marta
Author
dc.contributor.author
Mujica, Cristina
Author
dc.contributor.author
Bosch, Rubén
Author
dc.contributor.author
Farías, Gustavo
Author
dc.contributor.author
Fuentes, Patricio
Admission date
dc.date.accessioned
2019-01-29T17:57:07Z
Available date
dc.date.available
2019-01-29T17:57:07Z
Publication date
dc.date.issued
2006
Cita de ítem
dc.identifier.citation
Neurobiology of Aging, Volumen 27, Issue 2, 2018, Pages 237-244
Identifier
dc.identifier.issn
01974580
Identifier
dc.identifier.other
10.1016/j.neurobiolaging.2005.01.011
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/163932
Abstract
dc.description.abstract
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the presence of extracellular amyloid deposits, consisting largely of Aβ peptide and the presence of intraneuronal aggregates of neurofibillary tangles formed by tau. Development of cerebrospinal fluid (CSF) biomarkers has become a rapidly growing research field, considering the need for diagnostic tools for AD, thus allowing therapeutic compounds to have the greatest potential for being effective. We have focused on the relationships between critical biomarkers such as tau and Aβ in the CSF and the cognitive impairment of patients, as assessed by a battery of neuropsychological tests derived from CDR and CERAD, of value in the evaluation of AD patients. As part of a longitudinal study, we analyzed by ELISA and Western blots the levels and molecular patterns of hyperphosphorylated tau in the CSF of three different groups of patients: AD patients between 69- and 73-years-old, a group characterized with mild cognit